"Newly minted Nasdaq darling Chimerix (Nasdaq: CMRX) has announced the final study design for its lead candidate, a drug aimed at preventing viral infection in patients whose immunities have been compromised due to stem cell transplants.
Since the end of its Phase 2 meeting with FDA regulators last May, Chimerix has been working with the FDA to design its Phase 3 trial. The population, specifics and endpoints have now been established, which means the trial can start dosing this year. Topline data is expected in 2015.
In its IPO filing earlier this year, the Durham drug company indicated that money raised from the offering would go toward a Phase 3 trial.
After being priced at $14 earlier this month, Chimerix has kept up its stock price, trading at about $18.95 by early afternoon Wednesday"